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Summary.-Splenocytes from inbred Wistar rats bearing a syngeneic squamous
cell carcinoma (Spl) were fractionated by several techniques to characterize the
lymphoid cells cytotoxic to the tumour in vitro. The anti-tumour cytotoxicity is
presumably mediated primarily by T lymphocytes because it was greatly reduced
by removal of T lymphocytes with heterologous anti-T serum plus complement
but not by removal of other cell types. Cytotoxicity could be blocked at the tumour
cell but not at the effector cell by sera taken late in tumour growth. Sera taken
earlier in tumour growth could induce cytolysis of tumour cells by normal spleno-
cytes but only if the tumour cells were treated with serum and washed before addition
of the effector cells. Although splenocytes from normal and tumour-bearing rats
were equally effective at lysing antibody-coated target cells it is unlikely that this
mechanism is important in vivo as sera from early in tumour growth onwards
contained factors (immune complexes?) which inhibited antibody-induced lympho-
cytolysis.*
MANY humans and animals with
progressing tumours have cytotoxic lym-
phoid cells for the tumour in vitro and
this cytotoxicity can often be abrogated
by the host's serum (Hellstr6m and
Hellstrom, 1969). The serum factors
appear to be tumour-derived antigen,
specific antibody, or complexes of tumour
antigen and antibody aind they may
operate on either the lymphoid or the
tumour cell (Hellstr6m and Hellstrom,
1969; Sj6gren et al., 1971; Currie and
Basham, 1972; Baldwin, Price and Robins,
1972, 1973). In other studies, sera from
tumour-bearing animals have been shown
to increase cytolysis of tumour cells by
lymphoid cells (Pollack et al., 1973;
Basham and Currie, 1974).
A full understanding of the mechanism
of serum modulation of lymphocytolysis
requiires knowledge not only of the serum
factors but of the nature of the cytotoxic
lymphoid cell. In this paper, we ex-
amine both the cytotoxic lymphoid cells
and their modulation by serum factors
in rats bearing a syngeneic squamous
cell carcinoma.
MATERIALS ANI) METHODS
Rats and tumour.-Inbred Wistar rats
wvere inoculated subcutaneously in the medial
aspect of the right thigh with 104 syngeneic
squamous cell carcinoma cells (Spl). This
tumour is weakly immunogenic in the syn-
geneic host and has been shown to induce
some transplantation resistance in vivo
(Baldwin, 1966). WTe have shown previously
that splenic cytotoxicity is detectable from
4 weeks after tumour inoculation until death
of the animal after 8-9 weeks tumour growth
(Flannery et al., 1973a). In the local graft-
versus-host test of T cell function described
below, F1 hybrids between this Wistar
subline and DA (Agouti) rats were used.
* "Lymphocytolysis" is uised in this communmication to meant cytotoxicity by lymphoreticular
cells. "Antibody-induced" is ani abbreviation for any activation of such cells by antigen antibody
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Cytotoxicity against syngeneic squamnus
cell carcinoma cells.-Cytotoxicity tests were
carried out in Falcon microtitre plates (No.
3034, Falcon Plastics Co.) using a modifica-
tion (Flannery et al., 1973a) ofthe procedures
of Takasugi and Klein (1970). Spl tumour
cells in Medium 199 + 20% foetal calf
serum were incubated in the plates at 37°C
overnight. Adherent cells were counted by
phase contrast microscopy after washing,
and wells containing 50-100 cells were used
in all tests. Spleen cell suspensions were
then added to give a final effector to target
cell ratio of 100: 1. Six to 10 replicates
of each test and control well were used.
Plates were incubated for a further 40-48 h
at 37°C. Plates were washed, fixed with
methanol and adherent cells counted by
light microscopy. Cytotoxicity was cal-
culated as 100(Nc-Nt)/Nc where Ne and
Nt are respectively the mean number of
surviving tumour cells in wells with spleen
cells from either non-tumour-bearing or
tumour-bearing rats. In fractionation ex-
periments, cytotoxicity was expressed rela-
tive to non-fractionated control cells because
preliminary studies showed that fractionation
of control cells had little effect on the number
of surviving tumour cells.
Spleen cells from Spl tumour-bearing rats
were cytotoxic to Spl cells in vitro but not
to (i) another Wistar rat tumour (Walker
256 carcinoma), (ii) a mammary tumour
ofthis inbred line, (iii) normal lung histiocytes
from syngeneic animals, when compared
with control (non-immune) spleen cells
(Flannery, 1974).
Other assays of lyinphoid cell function.
Phytohaemagglutinin (PHA)-induced pro-
liferation of spleen cells was as described
by Matthews and Maclaurin (1973), antibody-
induced cytolysis of chicken erythrocytes
(CRBC) was assayed as described by Mat-
thews and Maclaurin (1974), and direct
plaque-forming cells (PFC) to sheep erythro-
cytes were assayed by the method of Cun-
ningham and Szenberg (1968).
Cell fractionation technique8
Fractionation ofspleen cells on aggregated
immunoglobulin (Agg Ig) columns on treat-
ment with iron carbonyl are described else-
where (Matthews, Rolland and Nairn, 1975).
Briefly, aggregated immunoglobulin coupled
to agarose was prepared by the method
of van Dalen, Knapp and Ploem (1973).
Agarose-Agg Ig slurry was poured into
5 ml syringes plugged with cotton wool,
washed with sterile saline and incubated
with saline plus 10% foetal calf serum for
at least 1 h at room temperature before
use.
Cell suspensions, 5 x 106 cells/ml bed
volume in 10% of the bed volume, were
allowed to flow into the columns which
w-ere then sealed and incubated vertically
for 30 min. Non-adherent cells were eluted
at 37°C at a flow rate of 10-20 ml/h. This
treatment markedly reduced the activity
of non-immune spleen cells in killing anti-
body-coated chicken erythrocytes (CRBC),
a function associated with Fe-receptor-
bearing cells (Perlmann, Perlmann and
Miiller-Eberhard, 1973). In a typical ex-
periment (Matthews et al., 1975), cytotoxicity
of non-fractionated spleen cells (44-7+3'5%)
was reduced after passage through anAgg Ig
column to 3 0 ± 288% (mean ± S.D.).
Phagocytic cells were removed from
spleen cell suspensions by incubation of 108
splenocytes with 0-3 g carbonyl iron (B.D.H.)
for 1 h at 37°C with occasional shaking.
Non-phagocytic cells were decanted, phago-
cytes being retained by a magnet. In three
experiments this gave a mean reduction
of 41% in the proportion of phagocytes as
determined on Leishman's stained smears.
Fractionation on nylon-wool columns was
according to Shellam (1974), except that
107 instead of 5 x 107 splenocytes were
applied to columns containing 0 3 g nylon
fibres.
(a) Treatment with a heterologous anti-l'
cell serun.-Two outbred rabbits weighing
2-5 kg received at weekly intervals, three
intravenous injections of respectively, 2 x 108
rat thymocytes, 6 x 107 nylon-wool-purified
lymph node cells, and finally 3 x 108
thymocytes. This regimen was adopted to
raise antibodies against peripheral T lympho-
cytes as well as thymocytes. The rabbits were
bled one week after the final injection, sera
were pooled, heat inactivated and absorbed
once with rat erythrocytes and thrice with
bone marrow cells (anti-T serum), or for
neutralization, twice with thymocytes and
once with nylon-wool-purified lymph node
cells.
To remove T lymphocytes from spleen
cell suspensions, 107 splenocytes in 0-9 ml
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were incubated for 15 min at 37°C with
01 ml of a 1 in 10 dilution of anti-T cell
serum. Guinea-pig complement (0.1 ml) wNas
added and after a further 30 min incubation
at 37°C, the cells wNere washed tw-ice, counted,
and resuspended at a concentration of
Trypan Blue-excluding cells w%hich gave
an effector: target ratio of 100: 1.
The specificity of the rabbit anti-rat T
cell serum studies w%ias confirmed by several
criteria. The lytic effect of anti-T serum
plus complement on lymphoid cell suspen-
sions from various organs w-as proportional
to their reported T cell content. A plateau
level of killing was observed only wtith
thymocytes, hence the anti-T cell serum
was used at the lowest dilution (1/10) giving
maximum lysis of thymocytes, i.e. 92%O.
Under these conditions the antiserum killed
50-60% of lymph node cells, 40-60%0 of
splenocytes and less than 5%O of bone marrow-
cells.
In addition, treatment of normal Wistar
spleen cells with anti-T cell serum plus
complement markedly reduced their ability
to generate a graft-versus-host reaction, an
accepted T lymphocyte function (Cantor,
1972), in the popliteal lymph node assay
of Ford, Burr and Simonsen (1970). Brieflv,
107 parental spleen cells were injected into
the hind footpads of F1 hybrid rats and the
popliteal node weights determined after
7 days. Contralateral footpads were injected
w?ith medium alone. Test lymph node
weights (means of groups of 3 ± S.D.)
after cell treatment with anti-T cell serum
plus complement wA,ere significantly lower
(20-7 + 3-9 mg) than after treatment with
antiserum alone, complement alone, normal
serum plus complement or after no treat-
ment (32-6 ± 10-4 mg; P < 001) by the
Mann-Whitney test.
(b) EAC' rosette separation. Rat spleno-
cytes were initially purified by centrifugation
over a modified Hypaque/ficoll mixture
(Parish and Hayward, 1974) for 10 min at
1200 g; the cells at the interface w%ere col-
lected, washed and resuspended at 5 x 106
cells/ml in medium. The methods of coating
sheep erythroeytes (E) with antibody (A)
and complement (C'), and EAC' rosette
formation with rat splenocytes are described
elsewhere (Matthews et al., 1975). After
rosette formation, the cell suspension wNas
layered on to 'modified" Hypaque/ficoll
and centrifuged at 1200 g for 10 min. There
wA-ere fewer EAC' rosette-forming cells at
the interface, Ahilst the pellet was enriched
in EAC'-positive cells. This latter popula-
tion Awas treated for 10 min at room tem-
perature wNith isotonic NH4CI solution to
lyse the erythrocytes and all cell populations
were washed twice, counted and resuspended
at the appropriate concentration for cyto-
toxicity testing. The proportion of EAC'
rosette-forming cells in each of the fractions
wAas then determined, no attempt being made
to classify the rosette-forming cells as
lymphocytes or other cell types.
ASerumi reactivity
(a) Effect of tum?our-bearer sera on cytolysis
of tumour cells by imnmu?ne splenocytes. For
pretreatment of tumour cells, 10 ,ul medium
or 1/5 diluted serum were incubated for 1 h
at 37°C with previously plated Spl cells
(50-100). After wN-ashing the microplates
once, immune spleen cells were added at
an effector: target ratio of 100 1 and the
assay wvas continued as described previously
(Flannery et al., 1973b).
For pretreatment of effector cells, 250 ,ul
of medium or 1/5 diluted serum were in-
cubated for 1 h at 37°C with 2 5 x 105
immune splenocytes. After washing once,
the effector cells were added at a ratio of
100: 1 to untreated Spl tumour cells in
microplates.
Results wN-ere expressed as the 00 reduction
in cytotoxicity for test serum treatment
relative to normal serum treatment.
(b) Capacity of tumour-bearer sera to
induce cytolysis of tumour cells by normial
splenocytes. Plated Spl cells w%-ere incubated
for 1 h at 37TC with 10 jul medium or with
serum diluted 1/5 or 1/50. After Awashing,
normal splenocytes wAere added to give an
effector: target ratio of 100: 1 and the
assay was continued as usual. Cytotoxicity
was expressed relative to control wells
containing medium in place of serum.
(c) Serum inhibition of antibody-induced
lysis of EB2 target cells by normal spleno-
cytes.-For the 5'Cr release assays (Matthews
and Maclaurin, 1974), the effector spleen
cells (2 x 106) in 0 4 ml medium were
incubated for 30 min at 37°C wN-ith 50 ,ul
of the test serum or medium, before addition
ofthe 5'Cr-labelled EB2 target cells (2 x 104)
plus anti-EB2 serum in a volume of 50 ,ul.
The final culture dilution of anti-EB2 serum
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was 1/5000 and 0 serum inhibition of
cytotoxicity was calculated from the expres-
sion 100(a -b)/(a- c) where a= ct/min
released by spleen cells + anti-EB2 + me-
dium, b = ct/min released by spleen cells +
anti-EB2 + test serum, c = ct/min released
by spleen cells + medium only.
Rat anti-EB2 serum was induced bygiving
two intraperitoneal injections of 107 EB2
cells, 2 weeks apart and bleeding 1 week
after the second injection.
RESULTS
Fffect of various fractionation procedures
on cytolysis of syngeneic tumour cells
Iron carbonyl treatment--Treatment
of spleen cells fromn tumour-bearing rats
with iron carbonyl had little effect on
anti-tumour cytotoxicity (Table 1), im-
plying that phagocytic cells do not
play a major role in the killing process.
These iron carbonyl-purified cell sus-
pensions had an increased response to
PHA (Tablet), indicating effective re-
TABLE I. Effect of Column Fractionation
immune Splenocytes on Cytolysis of Synge
Experiment
I Normal
Tumour-
bearing-
2 Normal
Tumour
bearirng-
3 Normal
Tumour-
bearing
4 Normal
Tuimour-
bearing
5 Normal
Tumour-
bearing-
Spleen cells
Noii-fractionate(d
rNon-fractionated
q Iron carbornyl treatedl
tAggIg coltumn eluate
Non-fractionated
TNon-fractionated
Iron carbonyl treate(c
tAgg Ig columin eluate
Non-fractionated
TNon-fractionated
Agg Ig column eluate
LNylon column eluate
Non-fractionated
fNon-fractionated
Agg Ig column eltuate
LNylon column eluate
Non-fractionated.
rNon-fractionated1
Ovalbumin column
L eluate
Ateani ttumou
cells/well
(1s
28-6± 3-2
18-2 -3-5
20-6 4-3
15-5 3-9
27-5 7-1
19-2 2-1
16-9±2-7
20-4±5-9
29-9 2-0
22-0 3-3
19-2 1*9
18-3 3-1
22-4 3-7
17-6 2-4
12-6±2-3
17-9 3-8
31-2 6-8
24-1 5-0
22-4 2-2
moval ofPHA-suppressor cells, i.e. phago-
cytes (Kirchner et al., 1974). Non-frac-
tionated spleen cells from tumour-bearing
rats had a much reduced PHA-response
compared with normal rats (Table 1).
Fractionation on aggregated immuno-
globulin (Agg Ig) columns.-Passage of
spleen cells from tumour-bearing
animals through Agg Ig or control
columns had little effect on cytotoxicity
(Table 1, Experiments 1-4). The efficacy
of the column separation was confirmed
either by increase in PHA-responsiveness
(Table 1) or in all experiments when
tested, by a loss in the capacity to kill
antibody-coated CRBC (see above). Else-
where, we have shown the Agg Ig columns
retain phagocytic cells, K cells and
antibody-forming cells but not T lympho-
cytes responsive to PHA or capable of
mediating graft-versus-host reaction (Mat-
thews et al., 1975). Thus the anti-tumour
cytotoxicity is unlikely to be mediated
or Iron Carbonyl Treatment of Tumour-
eneic Tumour Cells and on PHA-induced
ration
% Specific
cytotoxicity*
36-4
28-0
45 8
30-2
38-6t
25-8
26-4
35.8t
38-8t
21-4
43.8t
20-1
228
283
PHA stimtulation
(ct/min± s.d..)
Without With
PHA PHA
4191- 87 14794i 96
314 8 323± 61
203 : 121 2283±639t
246± 54 2173+189t
294 130 3527±213
94± 9 122+ 27
109± 21 889± 94
87- 16 756±106
N.D.
N.D.
N.D,
*Effector: target ratio = 100 : 1.
tSignificantly different from non-fractionated, J) <0(05 (Student's t test). 'N.D. not dlone.CHARACTERIZATION OF CYTOTOXIC SPLEEN CELLS
TABLE II.-Effect of Nylon Wool Column
Fractionation, Treatment with Anti-T
Serum and C', or EAC' Rosette Separation
on Number of PFC and on Antibody-
Induced Lymphoid Cell Lysis of Chicken
Erythrocytes
Experiment Spleen cells PFC/106
1 Non-treated 432
Nyloncolumn 158
eluate
2 Non-treated 170
C' 250
Anti-T+C' 350
3 Non-treated 180
C' 210
Anti-T+C' 275
4 Non-fractionated (42)
EAC' depleted (2)
EAC' enriched (65)
0/
,0
cytotox-
icity*
58-2
47-7t
95-8
90-2
59-2t
69-8
71-4
64.5
78-6
56-8t
19-9t
Figures in brackets represent % EAC' rosette-
forming cells.
* Effector: target ratio= 10:1, and final anti-
CRBC dilution = 1/2000.
f Significantly different fromnon-treated, P<0-05.
by phagocytic cells, K cells or antibodv-
forming cells.
Fractionation on nylon wool columns.-
Passage of cytotoxic cells through nylon
wool columns did not reduce cytotoxicity
(Table 1). Nylon wool columns have
been reported to remove both phagocytic
cells and Ig-bearing B lymphocytes from
rat spleen suspensions (Shellam, 1974)
thus giving an enriched population of
T cells. In our hands, nylon wool puri-
fication ofspleen cells reduced the number
of antibody-forming cells (Table II, ex-
periment 1) and increased the proportion
of T cells from 50+ 10% to 85+ 5%
as determined by C'-dependent lysis with
anti-T cell serum; it had little effect
on K cell function (Table II, Experi-
ment 1).
Retention of cytotoxicity after pas-
sage through nylon wool or Agg Ig
columns suggests that the effector
cells are T lymphocytes.
Treatment with anti-T serum plus
complement.-Antibody-dependent spleno-
cyte cytotoxicity against CRBC was
reduced to some extent by pre-treatment
of the effector cells with anti-T serum
and C' (Table II); possibly by inhibition
of effector cells by T lymphocyte-anti-
TABLE III.-Effect of Treatment with Anti-T Cell Serum and C' on Cytolysis of
Syngeneic Tumour Cells
Experiment Spleen cells
1 Normal Non-treated
Tumour- TgcNon-treated
bearing LAnti - T+C'
2 Normal Non-treated
Tumour- ,{Non-treated
bearing LAnti-T+C'
3 Normal Non-treated
rNon-treated
Tumour- J C'
bearing Anti-T±C'
NAbsorbed Anti-T+C't
4 Normal Non-treated
rNon-treated
Tumour- CAntiT
bearing- Abnti-T±C
Absorbed anti-T+C'j
Mean tumour
cell/well
±s.d.
35-9±4-8
26-3±2-8
29-3±5-4
36-2±4-7
44-4±6-3
32-3±3-9
33-2±4-0
40-6±5-7
36-3± 3-2
19-8±4-5
23-1±8-0
35-1 ±9-0
21-9±6-9
18-9±4-3
14.4±2-2
15-5±1-7
14-4±2-8
21-8±4-2
15-4±3-4
% EAC' rosette-
% Specific forming
cytotoxicity* cells
26-7
18-4
-0-8t
27-3
25-2
8-6t
45-5
36-4
3.3t
39.7
23-8
18-0
23-8
-15-3t
18-5
N.D.
N.D.
43
37
69
40
39
42
45
70
35
*Effector: target ratio = 100: 1.
t Significantly different from non-treated, P<0-01.
IAnti-T serum absorbed with T cells.
N.D. not done.
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TABLE IV.-Affect of EAC' Rosette Separation on Cytolysis ofSyngeneic
Tamoiir Cells
Spleenl cells
Non-fractionated
r Non-fractionated
- EAC' eniiched
(EAC' (leplete(l
Non-firactionate(d
rNon-fractionated
EAC' enriche(d
EAC' (leplete(1
Non-fractionate(1
{ Non-fractionate(d
EAC' enriched
EAC' (lepleted
Non-fractionate(d
{Non-fractionated(
EAC' enriched
L EAC' (leplete(l
AMean tumour
cells/well
±s.d.
47-7± 4-7
25-9±4-3
4:3- 34-2
:31-4-5-6
54-4± 6-9
34-6 7-0
57-0 5-3
45-8 9-4
25-8-4-7
14-9 4-1
23-4±4-8
19-744-7
25-3±5-7
16-2 2-7
22-1X2-:3
16-7 3-2
°, Specific
(.yetotoxicity *
45-7
9-2t
34- t
36-4
-4-8t
15-8t
42-
9-3t
23-6t
36-0
12-7t
34-2
0/ EAC' receptor-
bearinig cells
41
71
5
.38
65
6
43
63
8
.39
69
4
*Effector: target ratio 100: 1.
t Significantly (lifferent from non-fractionated, ' <0-05.
body complexes. Pre-treatment of im-
mune splenocytes with anti-T serum and
C' increased the proportion of EAC'
receptor-bearing cells (B lymphocytes
and phagocytes) (Table III) and anti-
body-forming cells (Table II) butmarkedly
reduced cytotoxicity against Spl tumour
cells (Table III). Neither C' alone (Table
III, experiments 1-4) nor anti-T cell serum
alone (Table III, experiment 4) signifi-
cantly reduced anti-tumour cytotoxicity.
The specificity of the anti-T serum was
confirmed by thymocyte absorptions:
this absorbed anti-T serum in the pres-
ence of C' did not kill cells from thvmus,
lymph node, spleen or bone-marrow and
did not significantly reduce anti-tumour
cytotoxicity (Table III, experiments 3
and 4).
EAC' rosette separation. Table IV
shows the effect on anti-tumour cytotox-
icity of separation of the effector spleno-
cytes into fractious either enriched or
depleted in EAC' receptor-bearing cells.
In all experiments, the population de-
pleted in EAC' receptor-bearing cells
was more cytotoxic than the enriched
fraction, excluding a primary role for B
lymphocytes and phagocytes. However,
as the EAC' receptor-depleted population
was significantly less cytotoxic than non-
fractionated splenocytes in 3 of 4 experi-
ments, it is possible that co-operation
between EAC'-positive and -negative
cell types is necessary for maximum
cytotoxicity. Alternatively, some dam-
age to the effector cells may result
from the fractionation.
Capacity of splenocytes fronm turmour-
bearing rats to kill antibody-coated
target cells
As splenic cytotoxicity against Spl
tumour cells is mediated primarily by T
lymphocytes and not via antibody-in-
duced lymphocytolysis, tumour-bearing
rats could in theory have fewer cells
capable of mediating this latter type
of cytotoxicity. From Fig. 1 it can be
seen that this is not so: splenocytes
from rats after 4-8 weeks of tumour
growth retained normal capacity to lyse
antibody-coated chicken erythrocytes in
a 5'Cr release assay. In addition, it can
be excluded that T cell anti-tumour
cytotoxicity predominates because of un-
suitability of the microplate assay for
Experimenit
1 Normal
Tumour-
bearing
2 Normal
Tutmour-
beariiig
3 NoIrmal
Tumour-
bearinlg
4 Normal
Tumour-
beariiigCHARACTERIZATION OF CYTOTOXIC SPLEEN CELLS
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Fig. 1. -ytolysis of antibodly-coate(l chicken
erythrocytes by splenocytes from tumour-
bearing not significantly different from normal
rats. Splenocytes from rats after 4-8 veeks of
tumour growth. Effector: target cell ratio
10: 1. Final anti-chicken-eIythrocyte ser-um
dilution 1/2000.
detecting antibody-induced lymphocyto-
lysis (Fig. 3).
Effect of tumour-bearing serum on lympho-
cytolysis
Mechanismn. of serum abrogation of
anti-tumour lymphocytolysis.-Pre-treat-
ment oftumour cells with rat serum taken
later in tumour growth (after 6 weeks)
protects the tumour cells from lysis
by cytotoxic splenocytes (Flannery et al.,
1973b). This is illustrated in Fig. 2, which
also shows that pretreatment of the
effector cells with " late " serum has little
effect on cytotoxicity. It appears that
the relevant serum factor is anti-tumour
antibody or complexes of this antibody
and tumour-derived antigen in antibody
excess. Pretreatment of tumour cells
with "late" serum never increased cyto-
toxicity by immune spleen cells.
Serum-dependent cytolysis of tumour
cells by normal 8plenocytes. Normal and
tumour-bearing sera were tested for their
capacity to induce cytolysis of tumour
cells by normal splenocytes (Fig. 3).
At one or both of the dilutions tested,
all Week 4 sera and one of three Week 6
20
0
-20_ I
EFFECTOR TUMOUR
CE L L CELL
Fig. 2. Decrease in anti-tumour cytotoxicity by
tumour serum pre-treatment of effector spleno-
cytes or tumour cells. Tie-lines indicate same
experiment. Sera an(l splenocytes respectively from rats after 6-8 weeks anid after 4-8 weeks
of tumour growth.
sera induced significantly more lympho-
cytolysis than the normal serum control
(P<0 05, Student's t test). C'-dependent
serum cytotoxicity is also maximum
after 4 weeks of tumour growth (Flan-
nery et al., 1973b) but has not been
detected at dilutions higher than 1/5.
This suggests that cytotoxicity by normal
splenocytes and 1/50 sera is due to anti-
body-induced cytolysis by K cells or
phagocytes and not to local production
of C' by splenocytes.
Antigen-antibody complexes in test
serum can inhibit non-specifically anti-
body-induced lymphocytolysis at the effec-
tor cell level (MacLennan, 1972). In
the experiments in Fig. 3, the tiumour
cells were treated with the test serum
I
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0
A
-101_
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2 4 6 8
NORMAL WEEKS OF TUMOUR GROWTH ANTI-
RAT
Fig. 3. Antibody-induced lysis of tumour cells by normal splenocytes plus normal or tumour-bearer sera
at dilution of 1/5 (*) or 1/50 (A). Points represent 5 experiments and 1 normal serum an(d either
3 or 4 tumour-bearer sera at each time interval. Increased lysis with sera from weeks 4 an(d 6. Rabbit
anti-rat-thymocyte serum includle(l as a positive control.
and washed before addition of the effec-
tor cells, which allows detection of anti-
body-induced lymphocytolysis; anyinhibi-
tory complexes are removed by washing.
Cytotoxicity does not occur if the effector
cells are added to the tumour cells without
first washing off the tested serum.
Detection of antigen-antibody com-
plexes in tumour-bearer serum by inhibi-
tion of antibody-induced splenocyte killing
of target cells. Fig. 4 compares the in-
hibitory effect of normal or tumour-
bearer sera on cytolysis of antibody-
coated EB2 cells by normal splenocytes
in a 5TCr-release assay. All groups of
sera from tumour-bearing rats (2, 4,
6 or 8 weeks) were significantly more
inhibitory than normal sera (P<0-02,
Wilcoxon rank sum test) suggesting
increased serum levels of antigen-
antibody complexes from 2 weeks
after tumour inoculation.
1)ISCUSSION
By several in vitro techniques, spleen
cell suspensions from tumour-bearing rats
were depleted of the various classes of
known effector cells. Cytotoxicity was
either increased or unaltered by treat-
ment of cytotoxic spleen cells with iron
carbonyl or passage through Agg Ig or
nylon wool columns, but markedly re-
duced by treatment with anti-T serum
and C'. Further evidence for an effector
T cell is that splenocyte fractions de-
pleted in EAC' receptor-bearing cells
(i.e. B lymphocytes and phagocytes)
were more cytotoxic than fractions en-
riched in these cells. Thus in the
squamous cell carcinoma-bearing rats, the
anti-tumour cytotoxicity measured by
our in vitro test is mediated primarily
by T lymphocytes.
In humans with melanoma (Wybran
et W., 1974) and rats with a Gross virus-CHARACTERIZATION OF CYTOTOXIC SPLEEN CELLS
@0
00
0
0
0
0
0
0
000
0@0
0
@000
It
0
00
0@
@0
0
0
0
0
0
0
0
@0
0
2 4
WEEKS OF TUMOUR
6
GROWTH
8
Fig. 4. -Increased inihibition by tumour-bearer sera, compared with normal, of antibodty-in(luce(l lymp)hocytolysis of EB2 target cells. Each point represents an in(livi(lutal seirim.
induced tumour (Shellam, 1974), in vitro
anti-tumour cytotoxicity is mediated by T
lymphocytes. In humans with colonic
carcinoma (Nind et al., 1975) and mice
with Moloney virus-induced tumours
(Lamon et al., 1973; Leclerc et al., 1973)
there is evidence of both T and non-T
effector cells, whilst in human bladder
carcinomas non-T cellkilling predominated
(O'Toole et al., 1974).
Several other points ofinterest emerged
in the present study. Firstly, the cyto-
toxic T cells were not retained on Agg
Ig columns although previously we have
shown that cytotoxic mouse T cells
withspecificityforalloantigens areretained
on such columns (Matthews et al., 1975).
This discrepancy is unexplained: it might
be due to species differences or to cytotoxic
T cells in a syngeneic system differing from
those in the allogeneic.
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The low PHA response of splenocytes
from tumour-bearing rats could be en-
hanced to an unusual degree by removal
of phagocytic cells, suggesting an in-
creased proportion of phagocytic PHA-
suppressor cells (Kirchner et al., 1974).
Indeed, histological studies have shown
that from four weeks of tumour growth
there is a progressive histiocytic infiltra-
tion of the spleen in this system (Flan-
nery, Muller and Nairn, 1975).
Sera from rats after 6 weeks of
tumour growth block spleen cell cytotox-
icity at the tumour cell level presumably
because they contain anti-tumour anti-
body. We have evidence that the block-
ing serum activity is associated with the
IgG fil-action of the serum (Chalmers,
unpublished). There is evidence from
allogeneic tumour systems that anti-
tumour antibody can block the T cell
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cytotoxicity (Bonavida, 1974; Todd,
Stulting and Berke, 1973). Because spleen
cells from the rats bearing the squamous
cell carcinoma were fully capable of
killing antibody-coated target cells in
an independent system, it would seem
that the presumptive late antibody to
tumour that blocks T cell cytotoxicity
is for some reason unable to activate K
cells or facilitate phagocytosis.
Pretreatment of tumour cells with
blocking serum taken at 6-8 weeks of
tumour growth failed to induce tumour
cell lysis by normal splenocytes, although
earlier sera (4-6 weeks) did promote
such lysis. Basham and Currie (1974)
showed similar effects in sarcoma-bearing
rats. In our assay, the tumour cells
were washed after treatment with serum
to remove any potentially inhibitory
antigen-antibody complexes before addi-
tion of the normal spleen cells. It is
well established that unrelated antigen-
IgG-antibody complexes can inhibit anti-
body-induced lymphocytolysis (Mac-
Lennan, 1972). Even from 2 weeks of
tumour growth, sera from tumour-
bearers were more effective than from
non-tumour-bearers in inhibiting anti-
body-induced lymphocytolysis, sug-
gesting that there are increased levels
of circulating immune complexes from
early in tumour growth. It remains to be
established that the antigen in these com-
plexes is tumour-derived. Whatever the
nature of the circulating immune com-
plexes, their presence would be expected
to exclude an effective in vivo role for
antibody-induced lymphocytolysis in re-
jection of the Spl tumour.
Although in certain circumstances,
T cell function can be non-specifically
inhibited by antigen-antibody complexes
(Gorczynski et al., 1975), it is unlikely that
such a non-specific effect can account for
serum abrogation of splenic cytotoxicity
against Spl tumour cells. Firstly the
blocking sera act only at the tumour
cell level and secondly, the effector T
cells do not bind Agg Ig (which is analo-
gous to antigen-antibody complexes).
Thus, at different stages ofSpl tumour
growth, two types ofanti-tumour cytotox-
icity can be detected by in vitro tests,
firstly, direct cytolysis by T lympho-
cytes and secondly antibody-induced
lymphocytolysis. Both types of cyto-
toxicity can be abrogated by serum
factors, different factors being respon-
sible in each case.
This work is supported by grants from
the National Health and Medical Re-
search Council and the Anti-Cancer Coun-
cil of Victoria. We thank Professor
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